Literature DB >> 10618400

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Y Shou1, M L Martelli, A Gabrea, Y Qi, L A Brents, A Roschke, G Dewald, I R Kirsch, P L Bergsagel, W M Kuehl.   

Abstract

Translocations involving c-myc and an Ig locus have been reported rarely in human multiple myeloma (MM). Using specific fluorescence in situ hybridization probes, we show complex karyotypic abnormalities of the c-myc or L-myc locus in 19 of 20 MM cell lines and approximately 50% of advanced primary MM tumors. These abnormalities include unusual and complex translocations and insertions that often juxtapose myc with an IgH or IgL locus. For two advanced primary MM tumors, some tumor cells contain a karyotypic abnormality of the c-myc locus, whereas other tumor cells do not, indicating that this karyotypic abnormality of c-myc occurs as a late event. All informative MM cell lines show monoallelic expression of c-myc. For Burkitt's lymphoma and mouse plasmacytoma tumors, balanced translocation that juxtaposes c-myc with one of the Ig loci is an early, invariant event that is mediated by B cell-specific DNA modification mechanisms. By contrast, for MM, dysregulation of c-myc apparently is caused principally by complex genomic rearrangements that occur during late stages of MM progression and do not involve B cell-specific DNA modification mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618400      PMCID: PMC26645          DOI: 10.1073/pnas.97.1.228

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.

Authors:  A Gabrea; P L Bergsagel; M Chesi; Y Shou; W M Kuehl
Journal:  Mol Cell       Date:  1999-01       Impact factor: 17.970

2.  Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11).

Authors:  M Thangavelu; O Olopade; E Beckman; J W Vardiman; R A Larson; T W McKeithan; M M Le Beau; J D Rowley
Journal:  Genes Chromosomes Cancer       Date:  1990-07       Impact factor: 5.006

3.  A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14.

Authors:  E Nacheva; P E Fischer; P D Sherrington; W Labastide; E Lawlor; E Conneally; C Blaney; F G Hayhoe; A Karpas
Journal:  Br J Haematol       Date:  1990-01       Impact factor: 6.998

4.  Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas.

Authors:  P A Lazo; J S Lee; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  Amplification of the c-myc and the pvt-like region in human multiple myeloma.

Authors:  M H Bakkus; K M Brakel-van Peer; J J Michiels; M B van 't Veer; R Benner
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

6.  Amylase-producing plasmacytoma cell lines, AD3 and FR4, with der(14)t(8;14) and dic(8)t(1;8) established from ascites.

Authors:  S Tagawa; S Doi; M Taniwaki; T Abe; Y Kanayama; J Nojima; K Matsubara; T Kitani
Journal:  Leukemia       Date:  1990-08       Impact factor: 11.528

7.  Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells.

Authors:  M Nobuyoshi; M Kawano; H Tanaka; H Ishikawa; O Tanabe; K Iwato; H Asaoku; A Sakai; A Kuramoto
Journal:  Br J Haematol       Date:  1991-04       Impact factor: 6.998

8.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).

Authors:  T J McDonnell; S J Korsmeyer
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

9.  Myelomonocytic myeloma cell line (LB 84-1).

Authors:  B G Durie; T M Grogan; C Spier; E Vela; V Baum; M A Rodriquez; Y Frutiger
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

10.  Establishment of five human myeloma cell lines.

Authors:  M Namba; T Ohtsuki; M Mori; A Togawa; H Wada; T Sugihara; Y Yawata; T Kimoto
Journal:  In Vitro Cell Dev Biol       Date:  1989-08
View more
  126 in total

1.  Molecular cloning of translocation breakpoint from der(8)t(3;8)(q27;q24) defines juxtaposition of downstream of C-MYC and upstream of BCL6.

Authors:  Takashi Sonoki; Hiro Tatetsu; Akitoshi Nagasaki; Hiroyuki Hata
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

2.  Establishment of CD5 and CD10 double-positive mature B-cell line, WILL1, showing complex 8q24 translocation involving 14q32 and 6q27.

Authors:  Shima Uneda; Minako Gotoh; Takashi Sonoki; Kazuhiro Nishida; Yasushi Nakamura; Miwa Kurimoto; Nobuyoshi Hanaoka; Hiroshi Matsuoka; Masafumi Taniwaki; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2008-10-30       Impact factor: 2.490

Review 3.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

Review 4.  Progress in the Management of Smoldering Multiple Myeloma.

Authors:  Timothy M Schmidt; Natalie S Callander
Journal:  Curr Hematol Malig Rep       Date:  2021-05-13       Impact factor: 3.952

5.  Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Authors:  Gina Y Kim; Ana Gabrea; Yulia N Demchenko; Leif Bergsagel; Anna V Roschke; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

6.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

Review 7.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

8.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

9.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

10.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Authors:  Ana Gabrea; Maria Luisa Martelli; Ying Qi; Anna Roschke; Bart Barlogie; John D Shaughnessy; Jeffrey R Sawyer; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2008-07       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.